Ileri Furkan Celebi, Acun Tolga
Department of Molecular Biology & Genetics, Zonguldak Bulent Ecevit University, Zonguldak, 67100, Turkey.
Biomark Med. 2021 Aug;15(12):941-950. doi: 10.2217/bmm-2020-0728. Epub 2021 Jul 8.
is associated with several cancers, but its biomarker potential in breast cancer is not adequately known. Q-RT-PCR, immunohistochemistry, COBRA methods and tools (KM-Plotter, UALCAN) were used to analyze the expression level, methylation status and prognostic value of in breast cancer. expression was significantly higher in clinical tumor samples compared with normal samples. High mRNA expression is associated with poor survival values in breast cancer. promoter region is hypomethylated in cell lines and clinical samples. High expression predicts poor clinical survival outcomes for breast cancer. Other than promoter methylation, epigenetic factors also warrant investigation in future studies as a regulatory mechanism of expression in breast cancer.
它与多种癌症相关，但其在乳腺癌中的生物标志物潜力尚未得到充分了解。采用定量逆转录聚合酶链反应（Q-RT-PCR）、免疫组织化学、亚硫酸氢盐修饰后测序法（COBRA）方法及工具（KM-Plotter、UALCAN）来分析其在乳腺癌中的表达水平、甲基化状态及预后价值。与正常样本相比，临床肿瘤样本中的表达显著更高。高mRNA表达与乳腺癌患者较差的生存值相关。其启动子区域在细胞系和临床样本中呈低甲基化状态。高表达预示着乳腺癌患者临床生存结局较差。除了启动子甲基化外，表观遗传因素作为乳腺癌中表达的一种调控机制，在未来研究中也值得探讨。
